FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Kit, Dna Detection, Human Papillomavirus
PMA: P160037
·
Supplement: S024
·
Decision Apr 2, 2026
Classifications
1
FEI Numbers
0
Registration Numbers
0
Basic Information
- Device Name
- Kit, Dna Detection, Human Papillomavirus
- Trade Name
- BD Onclarity HPV Assay
- PMA Number
- P160037
- Supplement Number
- S024
- Device Class
- FDA Class 3
- Product Code
- MAQ
- Generic Name
- KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS
- Medical Specialty
- Unknown
- Advisory Committee
- Microbiology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- April 2, 2026
- Date Received
- July 31, 2025
- Supplement Type
- Normal 180 Day Track
- Supplement Reason
- Change Design/Components/Specifications/Material
- Expedited Review
- N
Advisory Committee Statement
Approval for expanding settings under which self-collected vaginal (SV) specimens are collected and for adding a workflow for SV specimen processing and testing.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| MAQ | Kit, Dna Detection, Human Papillomavirus | FDA class 3 | Unknown |